Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
Sumitomo Chemical began its nucleic acid drug substance contract manufacturing business in 2013
Being a premium partner for pharmaceutical companies by contributing to safety and productivity of pharmaceutical manufacture
Approval is based on positive data from the Phase 3 ECHELON-3 trial
New Jersey-based manufacturing site to support innovative decentralized approach for improved patient experience
This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs
The company uses iPS cells to develop treatments for diseases relating to the kidney
Cellares will dedicate multiple Cell Shuttle and Cell Q systems with fully automated, high-throughput quality control for Bristol Myers Squibb’s exclusive use
Late-breaking data to be featured in an oral presentation at the American Association for Cancer Research (AACR) annual meeting on Monday, April 8 and highlighted as part of the official meeting press program
Subscribe To Our Newsletter & Stay Updated
